Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: population-based cohort study
While findings from this new study are encouraging, more robust and long-term research is needed before physicians can confidently prescribe GLP-1 medications to non-diabetic patients with obesity specifically for cancer risk reduction, he said.
[17] [18] Glibenclamide may occasionally be considered under specialist supervision when other options are unsuitable, with careful monitoring of the infant for signs of hypoglycaemia (poor feeding, jitteriness, unusual sleepiness)
This isnt just a minor inconvenienceits creating a fundamentally different environment for your gut bacteria
Youd need to take two separate medications, each with its own dosing schedule and side effect profile
Acknowledgements I would like to thank my former PhD students and post-docs Anne Raben, Anne Flint, Camilla Verdich, Birgitte Sloth, Helle Harder, Anita Belza and Thomas Meinert Larsen for their invaluable contributions to the research described in this article